Assertio Holdings, Inc.
NASDAQ:ASRTDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $151.86M
- Beta
- 0.53
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$5.55
Volume 0.27M
Average 0.33M
ASRT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Assertio Holdings, Inc.NASDAQ: ASRT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $58.58M, compared with -$12.17M a year earlier. Trailing-twelve-month accounts receivables was $4.77M. Over 3 fiscal years it compounded at +304.6% a year.
Context
- Accounts receivables amounted to 55.6% of revenue in FY2025, up 50.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $58.58M or moves back toward the trailing-twelve-month quarterly average of $1.19M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (65.99M) USD
- Year-over-year change
- -922.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (65.99M) | -922.0% |
| FY2024 | 2024-12-31 | (6.46M) | -113.3% |
| FY2023 | 2023-12-31 | 48.67M | +4986.4% |
| FY2022 | 2022-12-31 | (996K) | -8954.5% |
| FY2021 | 2021-12-31 | (11K) | — |
Accounts Receivables vs competitors
How ASRT compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +120.1% is the 5th highest of 7, against a peer median of +311.4%.
- Accounts receivables amounts to 4.7% of revenue for ASRT, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.45M USD | +434.5% | — | 16.2% | |
| LTM Mar 2026 | $6.8M USD | -23.8% | +58.7% | 10.3% | |
| LTM Jun 2025 | ₪4.94M ILS | +2249.6% | — | 2.0% | |
| LTM Mar 2026 | $4.77M USD | +120.1% | +304.6% | 4.7% | |
| LTM Mar 2026 | $3M USD | +188.4% | — | 3.4% | |
| LTM Mar 2026 | $412K USD | +34.2% | -57.2% | — | |
| LTM Apr 2026 | $91.5K USD | +1117.6% | +2.3% | 5.1% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding ASRT) | — | +311.4% | +2.3% | 4.2% | |
Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.28M) | 109.63M | (331.94M) | (21.58M) | (30.38M) |
| Depreciation & Amortization | 29.08M | 33.4M | 28.23M | 25.83M | 30.01M |
| Deferred Income Tax | 0 | (80.38M) | 76.2M | 0 | 0 |
| Stock-Based Compensation | 3.55M | 7.5M | 9.16M | 5.01M | 3.45M |
| Change in Working Capital | (31.29M) | (13.01M) | 140K | 5.2M | (45.33M) |
| Accounts Receivables | (11K) | (996K) | 48.67M | (6.46M) | (65.99M) |
| Inventory | 4.27M | (6.59M) | (4.97M) | (9.58M) | 9.68M |
| Accounts Payables | (28.7M) | (10.11M) | (29.35M) | (1.26M) | (13.29M) |
| Other Working Capital | (6.85M) | 4.69M | (14.21M) | 22.5M | 24.27M |
| Other Non-Cash Items | 5.48M | 21.46M | 267.82M | 11.95M | 14.07M |
| Operating Cash Flow | 5.52M | 78.6M | 49.6M | 26.41M | (28.18M) |
| Capital Expenditures | (53K) | (274K) | (628K) | 0 | 0 |
| Acquisitions (Net) | (18.47M) | (42.4M) | 1.53M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (98.61M) | (119.2M) |
| Sales of Investments | 0 | 0 | 2.19M | 49.69M | 115.38M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (8.17M) |
| Investing Cash Flow | (18.53M) | (42.67M) | 3.1M | (48.91M) | (11.99M) |
| Debt Repayment | (9.84M) | (750K) | (10.5M) | 0 | 0 |
| Common Stock Issued | 44.86M | 7.02M | 0 | 0 | 0 |
| Common Stock Repurchased | (418K) | (838K) | (7.9M) | (350K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.58M) | (13.23M) | (25.8M) | 0 | (189K) |
| Financing Cash Flow | 29.03M | (7.79M) | (44.2M) | (350K) | (189K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.02M | 28.13M | 8.5M | (22.85M) | (40.36M) |
| Free Cash Flow | 5.47M | 78.32M | 48.98M | 26.41M | (28.18M) |
Assertio Holdings, Inc.
NASDAQ:ASRT
Intrinsic Alpha fair value
Locked
Current Price
$23.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.